ZYNE Zynerba Pharmaceuticals Inc.

-0.22  -2%
Previous Close 11.36
Open 11.36
Price To book 2.34
Market Cap 150990145
Shares 13,553,873
Volume 176,478
Short Ratio 5.82
Av. Daily Volume 326,480

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 2H 2018.
Tourette Syndrome
Development to be discontinued - noted January 2018.
Development to be discontinued - noted January 2018.
Peripheral Neuropathic Pain (PNP)
Phase 2 data released September 28, 2017. Company noted data were positive with primary endpoint met. Phase 2/3 trial to commence mid-2018 with data due 2019.
Fragile X syndrome
Phase 2 data released August 14, 2017 - primary endpoint not met. Noted January 2018 that development will be discontinued.
Phase 2 data released August 7, 2017 - endpoints not met. Phase 2b trial to be initiated 2H 2018.
ZYN002 - STAR 1
Adult Epilepsy Patients with Refractory Focal Seizures

Latest News

  1. Can Zynerba Pharma Shares Really Still Double in These High Times?
  2. Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update
  3. Can This Beaten-Down Marijuana Stock Roar Back in 2018?
  4. Canada’s Cannabis Market Could Be About To Explode
  5. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE): Does -3.8% EPS Drop In A Year Reflect The Long-Term Trend?
  6. Today’s Research Reports on Trending Tickers: Achillion Pharmaceuticals and Zynerba Pharmaceuticals
  7. Zynerba Pharmaceuticals Volatile After Epilepsy Study Results
  8. Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 Annual Meeting of the American Epilepsy Society (AES)
  9. Zynerba Pharmaceuticals Announces Poster Presentation at the 2017 Annual Meeting of the American Epilepsy Society (AES)
  10. Is It The Right Time To Buy Zynerba Pharmaceuticals Inc (ZYNE)?
  11. Zynerba reports 3Q loss
  12. 3 Marijuana Stocks That Like to Live Life Dangerously
  13. Like a Weed, This Marijuana Stock Catapulted Higher by 34% Last Week
  14. Zynerba's Recent Results Revitalize The Bull Case, But Risks Remain
  15. Zynerba Stock: Where Is It Headed From Here?
  16. Microchip Technology, United Continental and Zynerba Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
  17. Today's Research Reports on Stocks to Watch: Zynerba Pharmaceuticals and Loxo Oncology